Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 44

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 8
Chunk 44
---
 Hospital
in Adelaide, Australia and Pindara Private Hospital in the Gold Coast section of Australia. We have also trained a third hospital, GenesisCare
North Shore in Sydney, Australia, and have received ethics committee and research governance approval for that institution. The site will
be activated and open for enrollment pending completion of the site investigation meeting scheduled for February 2025. In late January
2025, Royal Adelaide Hospital successfully administered the Hemopurifier treatment to the first patient, with no adverse events.

We have received ethics committee approval from
Medanta Medicity Hospital in Gurugram, India for a similar nine to 18-patient, safety, feasibility and dose-finding trial. We are
completing the necessary logistical steps before they can open for patient enrollment.

We have entered into an agreement with North American
Science Associates, LLC (“NAMSA”), a world leading medical technology contract research organization (“CRO”) offering
global end-to-end development services, to oversee our clinical trials of the Hemopurifier for patients in Australia with various types
of cancer tumors. We also have engaged Qualtran LLC as the CRO for our clinical trial in India.

We also believe that the Hemopurifier can be part
of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an
already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus (“HIV”), hepatitis-C and Ebola.

     8 

Additionally, in vitro, the
Hemopurifier has been demonstrated to capture H5N1 bird flu virus, H1N1 swine flu virus, Zika virus, Lassa virus, MERS-CoV,
cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related
viruses, and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with
leading government or non-government research institutes.

On June 17, 2020, the FDA approved a supplement
to our open Investigational Device Exemption (“IDE”) for the Hemopurifier in viral disease to allow for the testing of the
Hemopurifier in patients with SARS-CoV-2/COVID-19, or COVID-19